Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289661 · ClinicalTrials.gov registry record · Phase 3
Descemet Endothelial Thickness Comparison Trial I
A Phase 3 study of Fuchs, sponsored by Stanford University.
- Active
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 7
- Study locations
NCT05289661: Active Phase 3 study of Fuchs, sponsored by Stanford University.
NCT05289661 is a Phase 3 study of Fuchs that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 160 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05289661, a Phase 3 study of Fuchs, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 7
- Study locations
Study Summary
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.
Primary Outcome
Best spectacle-corrected visual acuity
Conditions Studied
Interventions
- DRUG Topical Ripasudil
- DRUG Topical Placebo
Study Locations (7)
California
- Stanford University - Palo Alto
- University of California Davis - Sacramento
Pennsylvania
- University of Pennsylvania - Philadelphia
- Wills Eye Hospital - Philadelphia
Florida
- University of Miami - Palm Beach Gardens
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 3 |
What the registry record for NCT05289661 still lists
NCT05289661 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Fuchs appearing as the primary indexed condition, and to 2 interventions - of which Topical Ripasudil is the first listed.
NCT05289661 lists 7 locations in 5 states (California, Pennsylvania, Florida).
Frequently Asked Questions
What is clinical trial NCT05289661 about?
NCT05289661 is a clinical study titled "Descemet Endothelial Thickness Comparison Trial I". Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplan...
What is the current status of trial NCT05289661?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2022-07-15. Estimated completion is 2027-11-30.
What conditions does trial NCT05289661 study?
This clinical trial studies the following conditions: Fuchs.
What interventions are being tested in trial NCT05289661?
The interventions under investigation include: Topical Ripasudil (DRUG), Topical Placebo (DRUG).
Who is sponsoring clinical trial NCT05289661?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05289661 being conducted?
This trial has 7 study locations across California, Florida, New Hampshire, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fuchs
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05289661's enrollment target sits among peer trials
160 1480th of 2000 higher than 500 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI